跳至主要内容
临床试验/NCT00232167
NCT00232167终止3 期

Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Tolerability Of Indiplon Therapy Initiated With Sertraline Versus Sertraline Monotherapy In Subjects With Insomnia And Co-Existing Major Depressive Disorder

Neurocrine Biosciences0 个研究点目标入组 380 人开始时间: 2005年11月最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
终止
入组人数
380
主要终点
Change from baseline to week 1 in subjective total sleep time (sTST); (average of the week one data)

研究概览

简要总结

The goal of this study is to determine whether indiplon, when administered with sertraline, improves insomnia symptoms and depressive symptoms in subjects with both insomnia and depression.

详细描述

This Pfizer run study stopped due to the co-development program for indiplon being terminated between Pfizer and Neurocrine. The study was terminated on 16 November 2006. There were no safety issues leading to the decision to terminate this study.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • DSM-IV defined insomnia
  • DSM-IV defined Major Depression

排除标准

  • Current suicidal ideation or behavior
  • Primary sleep disorder other than insomnia

结局指标

主要结局

Change from baseline to week 1 in subjective total sleep time (sTST); (average of the week one data)

次要结局

  • Change from baseline in subjective total sleep time (sTST). Change from baseline in subjective parameters: LSO, sWASO, sNAASO, Sleep Quality (IVR). Change from baseline in the 3-item HAM-D insomnia factor (items #4-6).

研究者

申办方类型
Industry

相似试验